Kiyatec, a Greenville-based biotechnology company specializing in 3D cell culture technology, has promoted Eric Perreault to CEO.
As CEO, Perreault will continue to lead Kiyatec in its mission to revolutionize cancer care by harnessing the power of functional precision medicine with its KIYA-Predict and 3D Predict platforms, a news release stated. He succeeds Matt Gevaert, who, after more than 15 years as CEO, will remain a member of Kiyatec’s board of directors.
“We are excited to announce Eric Perreault as the new CEO of Kiyatec,” said Gevaert, co-founder of Kiyatec, in the release. “Eric’s leadership and extensive understanding of both our technology and industry are assets that will drive Kiyatec’s continued growth. We’re confident that, under Eric’s guidance, Kiyatec will make a meaningful and enduring contribution to cancer treatment and drug discovery.”
As President of Kiyatec, Perreault has been an integral part of the Kiyatec team and has played a crucial role in shaping the company’s strategic direction, the release stated. With his industry experience and leadership acumen, Perreault’s promotion to CEO marks a significant milestone in Kiyatec’s journey. In this new position, Perreault will work to propel Kiyatec toward commercial success by driving innovation, forging strategic partnerships, and expanding market reach.
Related content: Greenville medical company secures $18M in Series C fundraising
“In my new role as CEO, my mission is to drive Kiyatec toward truly revolutionizing cancer care, especially for patients battling brain cancer, who haven’t seen any real treatment advances in decades,” said Perreault in the release. “I’m eager to continue collaborating with Matt as a member of our board and tapping into his extensive experience to propel us toward accomplishing this ambitious goal.”p